Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan + Toripalimab in Advanced/Recurrent Endometrial Cancer
NCT06548763Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan and toripalimab in endometrial cancer (EC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
topotecantoripalimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06548763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548763.